NSIP vs IPF: How Are These Lung Diseases Different?

Non-specific interstitial pneumonia (NSIP) and idiopathic pulmonary fibrosis (IPF) are both interstitial lung diseases, but they have very different causes, treatments, and expected outcomes. The most important difference is that IPF is a specific, progressive disease of unknown cause, whereas NSIP is a pattern of lung damage that is often triggered by an identifiable underlying cause, such as an autoimmune disease ^{[1] [2]}.

The Most Important Concept: Pattern vs. Diagnosis

Before comparing the two, it helps to understand a key medical concept that can cause confusion when reading your medical records:

• NSIP and UIP (Usual interstitial pneumonia) are patterns of damage seen on a scan or biopsy.
• IPF is a clinical diagnosis. It is diagnosed only when a patient has a UIP pattern and doctors have ruled out all other known causes ^[1].

If your scan report mentions a “UIP pattern,” it does not automatically mean you have IPF. A UIP pattern can also be caused by connective tissue diseases, environmental exposures, or chronic hypersensitivity pneumonitis.

Who Gets It and What Causes It

• IPF: Typically affects older adults (often age 60 or older) and is more common in men and those with a history of smoking ^{[3] [4]}. To diagnose IPF, doctors must exclude known causes. This means they will ask detailed questions about your work history, hobbies, and exposures (like mold, birds, asbestos, or farming dusts) and perform blood tests to check for autoimmune diseases ^[1].
• NSIP: Can affect anyone, but is more frequently seen in women, especially when linked to an underlying condition ^[4]. The NSIP pattern is very commonly caused by connective tissue diseases (autoimmune conditions) like scleroderma, rheumatoid arthritis, or inflammatory myositis ^[2]. It can also be triggered by medications or environmental exposures.

Differences on High-Resolution CT Scans (HRCT)

Radiologists look for visual clues on your scans to determine the pattern of lung damage.

• The NSIP pattern typically shows haziness (called ground-glass opacities), fine web-like lines (reticulation), and widened airways (traction bronchiectasis) mostly in the lower parts of the lungs ^{[5] [1]}. A helpful clue is subpleural sparing—where the very outer edges of the lungs remain relatively clear ^[5]. This occurs in roughly 30% to 40% of NSIP cases, so its absence does not rule NSIP out ^{[5] [6]}.
• The UIP pattern (the pattern of IPF) involves heavy scarring at the bases and outer edges (subpleural regions) of the lungs ^{[1] [5]}. A classic sign is honeycombing, which looks like clusters of small, thick-walled cysts ^[5].

While honeycombing strongly supports a UIP pattern, it is not unique to IPF and can occur in other advanced fibrotic lung diseases ^[5]. Additionally, severe, fibrotic NSIP can sometimes cause clustered cysts that mimic honeycombing, which is why expert review of your scans is important ^[7].

Differences Under the Microscope (Biopsy)

A lung biopsy is not a routine next step. Because biopsies carry real risks (like bleeding, infection, or triggering a flare-up), they are only considered if the results would change your treatment plan and your care team determines you are healthy enough for the procedure ^[8]. Many patients are diagnosed without one. If a biopsy is performed, pathologists look for:

• Temporal uniformity (in NSIP): The inflammation and scarring look like they happened at the same time and are evenly spread throughout the tissue ^{[9] [10]}.
• Temporal heterogeneity (in UIP): The tissue has a patchy mix of normal lung, old scar tissue, and areas of active, new scarring called fibroblastic foci ^{[9] [10]}. Finding a few fibroblastic foci does not automatically prove IPF, as they can occasionally appear in NSIP as well ^{[11] [12]}.

Treatment and Outlook

Treatment depends entirely on the specific diagnosis, the underlying cause, and whether the disease is more inflammatory or more fibrotic (scarred).

• NSIP: Some forms of NSIP are driven by inflammation (cellular NSIP) and may respond well to systemic corticosteroids or other immunosuppressive medications ^{[13] [14]}. However, if the NSIP is heavily scarred (fibrotic NSIP), immunosuppression may be less effective. These drugs also carry infection risks that must be monitored. Overall, NSIP generally has a better prognosis than IPF, but the outlook varies widely based on the subtype, severity, and response to treatment ^{[14] [15]}.
• IPF: Immunosuppressants are not the standard treatment for IPF. It is a chronic, progressive fibrotic disease treated with antifibrotic medications (such as pirfenidone or nintedanib), which aim to slow down the rate of scarring ^{[16] [17]}.
• Progressive Pulmonary Fibrosis (PPF): Sometimes, non-IPF conditions like fibrotic NSIP continue to worsen over time despite therapy. In these cases of progressive pulmonary fibrosis, doctors may prescribe antifibrotic medications to help slow the decline, as these drugs have been approved for this use in many regions ^{[17] [14]}.

Supportive Care: Regardless of the diagnosis, care also involves pulmonary rehabilitation, oxygen therapy if needed, keeping up with vaccinations, and monitoring your symptoms ^{[16] [18]}. If you experience sudden or rapidly worsening shortness of breath, or chest pain, seek prompt medical attention, as this could signal an acute exacerbation or infection ^{[19] [20]}.

The Importance of a Team Approach

Because patterns overlap, your diagnosis should be made through a multidisciplinary discussion (MDD) ^[8]. This means your pulmonologist, a specialized radiologist, and a pathologist (if a biopsy was done) review your history, exposures, scans, and tissue together to reach a consensus ^{[21] [22]}. Patients evaluated by a multidisciplinary team receive more accurate diagnoses, ensuring the right treatment path from the start ^[23].

At a Glance Comparison